Equity Details
Price & Market Data
Price: $14.03
Daily Change: +$0.03 / 0.21%
Daily Range: $13.68 - $14.22
Market Cap: $74,214,136
Daily Volume: 81,204
Performance Metrics
1 Week: -1.75%
1 Month: 69.04%
3 Months: 192.3%
6 Months: 180.5%
1 Year: 482.8%
YTD: 155.6%
About Rallybio Corporation (RLYB)
Get the full story on Rallybio Corporation (RLYB). Price: 14.03, daily change: +$0.03 / 0.21%. Market cap: 74,214,136. Performance from YTD to 1-year is available.
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.